EUVIMEDEUVIMED entdecken
Crossref

Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling

Feng-Yang Wang, Liang-Mei Yang, Xiao-Lin Xiong, Jing Yang, Yan Yang, Jiu-Qin Tang, Lei Gao, Yuan Lu, Yuan Wang, Taotao Zou iD, Hong Liang, Ke-Bin Huang iD

Journal of Medicinal Chemistry · 22.08.2024 · 67 (16) · 13778-13787

DOI: 10.1021/acs.jmedchem.4c00583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.08.2024. Verfasst von Feng-Yang Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medici…. Hauptthemen laut MEDLINE: Rhodium, Wnt Signaling Pathway, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metal-based chemoimmunotherapy has recently garnered significant attention for its capacity to stimulate tumor-specific immunity beyond direct cytotoxic effects. Such effects are usually caused by ICD via the activation of DAMP signals. However, metal complexes that can elicit antitumor immune responses other than ICD have not yet been described. Herein, we report that a rhodium complex (Rh-1) triggers potent antitumor immune responses by downregulating Wnt/β-catenin signaling with subsequent activation of T lymphocyte infiltration to the tumor site. The results of mechanistic experiments suggest that ROS accumulation following Rh-1 treatment is a critical trigger of a decrease in β-catenin and enhanced secretion of CCL4, a key mediator of T cell infiltration. Through these properties, Rh-1 exerts a synergistic effect in combination with PD-1 inhibitors against tumor growth in vivo. Taken together, our work describes a promising metal-based antitumor agent with a noncanonical mode of action to sensitize tumor tissues to ICB therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhodiumWnt Signaling PathwayAntineoplastic AgentsAnimalsHumansMicebeta CateninCoordination ComplexesCell Line, TumorReactive Oxygen SpeciesMice, Inbred C57BL

Substanzen

RhodiumAntineoplastic Agentsbeta CateninCoordination ComplexesReactive Oxygen Species

Autor:innen und Institutionen

  • State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovati…
  • Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou 510006, China.

ORCID-Profile: Taotao Zou, Ke-Bin Huang

Förderung

  • Natural Science Foundation of Guangxi Zhuang Autonomous Region
  • National Natural Science Foundation of China

Zitieren

APA

Wang, F. Y., Yang, L. M., Xiong, X. L., Yang, J., Yang, Y., Tang, J. Q., Gao, L., Lu, Y., Wang, Y., Zou, T., Liang, H., & Huang, K. B. (2024). Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling. Journal of Medicinal Chemistry, 67(16), 13778-13787. https://doi.org/10.1021/acs.jmedchem.4c00583

Vancouver

Wang FY, Yang LM, Xiong XL, Yang J, Yang Y, Tang JQ, et al. Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling. Journal of Medicinal Chemistry. 2024;67(16):13778-13787. doi:10.1021/acs.jmedchem.4c00583

BibTeX
@article{Wang2024,
  author = {Wang, Feng-Yang and Yang, Liang-Mei and Xiong, Xiao-Lin and Yang, Jing and Yang, Yan and Tang, Jiu-Qin and Gao, Lei and Lu, Yuan and Wang, Yuan and Zou, Taotao and Liang, Hong and Huang, Ke-Bin},
  title = {Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {16},
  pages = {13778--13787},
  doi = {10.1021/acs.jmedchem.4c00583}
}
Kostenlos starten →